Company Profile

Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.

Employees

Sector

Biotechnology & Medical Research

More about the company

11-18	Neuropathix, Inc. announced a financing transaction	CI
24/05/22	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
15/04/22	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
15/04/22	Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/03/22	Neuropathix, Inc. announced that it has received $0.15 million in funding	CI
12/11/21	Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
12/08/21	Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	CI
06/08/21	Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
13/05/21	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
30/03/21	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
10/02/21	Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC	CI
12/01/21	Neuropathix, Inc. Appoints Daniel Richman to Board of Advisors	CI
12/11/20	Neuropathix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI

24/05/22	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
25/04/22	Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021	PU
15/04/22	NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
25/03/22	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
12/11/21	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ

Manager	Title	Age	Since
Dean Petkanas CEO	Chief Executive Officer	47	25/07/2018
William Kinney CTO	Chief Tech/Sci/R&D Officer	68	25/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
05/01/22	Dean Petkanas	Sell	Chief Executive Officer	720,000	0.7923%
05/01/22	Dean Petkanas	Sell	Chief Executive Officer	180,000	0.1981%
05/01/22	Dean Petkanas	Sell	Chief Executive Officer	800,000	0.8803%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUROPATHIX, INC.	-.--%	-.--%	-	-	29.31K
ARGENX SE	+2.95%	+4.60%	+70.86%	+119.28%	55.19B
WUXI APPTEC CO., LTD.	+4.60%	+3.02%	+57.38%	+62.27%	45.75B
BIONTECH SE	-1.44%	+0.39%	-14.68%	-15.42%	22.98B
INSMED INCORPORATED	-2.69%	-2.10%	-6.70%	+363.03%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	-0.26%	-0.58%	+25.47%	-18.57%	16.26B
GENMAB A/S	+0.06%	+2.67%	+20.95%	-37.15%	15.42B
EXELIXIS, INC.	-1.01%	-2.30%	+28.59%	+173.07%	13.05B
PHARMAESSENTIA CORPORATION	+4.95%	+11.70%	+125.78%	+261.94%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.63%	-6.39%	+19.78%	-	12.37B
Average	+0.14%	+2.28%	+36.38%	+113.56%	23.8B
Weighted average by Cap.	+1.20%	+1.51%	+41.92%	+105.32%

Neuropathix, Inc. Stock

Stocks

NPTX

US64132Q1094

Biotechnology & Medical Research

Latest news : Neuropathix, Inc.

Press Releases: Neuropathix, Inc.

Managers and Directors: Neuropathix, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile